Aurora Innovation, BYD, and Tempus AI are just three of Lingotto Innovation’s holdings with explosive growth potential.

Tempus AI, Inc.'s unique data assets and AI-driven oncology solutions make it a promising buy. Click to read more on why the ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Today, Zacks Investment Ideas feature highlights Palantir PLTR, Tempus AI TEM and Comfort Systems USA FIX. These 3 AI-Relate ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this. After all, ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

A technology company specializing in the application of artificial intelligence to advance precision medicine and patient ...

"By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

In its first-quarter 2025 investor letter, Baron Discovery Fund highlighted stocks such as Tempus AI, Inc. (NASDAQ:TEM) . Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company.